Trial Profile
Phase I/IIa Trial Evaluating scAAV1.tMCK.NTF3 for Treatment of Charcot-Marie-Tooth Neuropathy Type 1A (CMT1A)
Status:
Suspended
Phase of Trial:
Phase I/II
Latest Information Update: 17 Mar 2023
Price :
$35
*
At a glance
- Drugs ScAAV1 tMCK NTF3 (Primary)
- Indications Charcot-Marie-Tooth disease
- Focus Adverse reactions
- 13 Mar 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 13 Mar 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Mar 2024.
- 14 Mar 2022 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jul 2020 to 1 Aug 2022.